Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods

Pain

Volumn 128, Issue 3, 2007, Pages 209-214

  Fusayasu, Emi ^a   Kowa, Hisanori ^a   Takeshima, Takao ^a   Nakaso, Kazuhiro ^a   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme (ACE); Calcitonin gene related peptide (CGRP); Headache; Migraine; Substance P

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; SUBSTANCE P;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE WITH AURA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY; STATISTICAL ANALYSIS; VEIN;

ADULT; BIOLOGICAL MARKERS; CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PEPTIDYL-DIPEPTIDASE A; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; SUBSTANCE P;

EID: 33847689071     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.09.017     Document Type: Article

References (46)

1. Ashina M., Bendtsen L., Jensen R., Schifter S., and Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 86 (2000) 133-138
2. Bellamy J., Bowen E.J., Russo A.F., and Durham P.L. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci 23 (2006) 2057-2066
3. Bender W.I. ACE inhibitors for prophylaxis of migraine headaches. Headache 35 (1995) 470-471
4. Cambien F., Alhenc-Gelas F., Herbeth B., Andre J.L., Rakotovao R., Gonzales M.F., et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet 43 (1988) 774-780
5. Costerousse O., Danilov S., and Alhenc-Gelas F. Genetics of angiotensin I-converting enzyme. Clin Exp Hypertens 19 (1997) 659-669
6. D'Amico D., Ferraris A., Leone M., Catania A., Carlin A., Grazzi L., and Bussone G. Increased plasma nitrites in migraine and cluster headache patients in interictal period: basal hyperactivity of l-arginine-NO pathway?. Cephalalgia 22 (2002) 33-36
7. de Hoon J.N., Smits P., Troost J., Struijker-Boudier H.A., and Van Bortel L.M. Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects. Cephalalgia 26 (2006) 56-63
8. Fiermonte G., Pierelli F., Pauri F., Cosentino F.I., Soccorsi R., and Giacomini P. Cerebrovascular CO2 reactivity in migraine with aura and without aura. A transcranial Doppler study. Acta Neurol Scand 92 (1995) 166-169
9. Fiscus R.R., Gross D.R., Hao H., Wang X., Arden W.A., Maley R.H., et al. N Omega-nitro-l-arginine blocks the second phase but not the first phase of the endothelium-dependent relaxations induced by substance P in isolated rings of pig carotid artery. J Cardiovasc Pharmacol 20 (1992) S105-S108
10. Goadsby P.J., Edvinsson L., and Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23 (1988) 193-196
11. Goadsby P.J., Edvinsson L., and Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28 (1990) 183-187
12. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Engl J Med 346 (2002) 257-270
13. Goldstein D.J., Offen W.W., Klein E.G., Phebus L.A., Hipskind P., Johnson K.W., et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21 (2001) 102-106
14. Goodman E.C., and Iversen L.L. Calcitonin gene-related peptide: novel neuropeptide. Life Sci 38 (1986) 2169-2178
15. Harer C., and von Kummer R. Cerebrovascular CO2 reactivity in migraine: assessment by transcranial Doppler ultrasound. J Neurol 238 (1991) 23-26
16. Harrison S., and Geppetti P. Substance P. Int J Biochem Cell Biol 33 (2001) 555-576
17. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1-96.
18. Jansen I., Uddman R., Ekman R., Olesen J., Ottosson A., and Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides 13 (1992) 527-536
19. Kastrup A., Thomas C., Hartmann C., and Schabet M. Cerebral blood flow and CO2 reactivity in interictal migraineurs: a transcranial Doppler study. Headache 38 (1998) 608-613
20. Kowa H., Fusayasu E., Ijiri T., Ishizaki K., Yasui K., Nakaso K., et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett 374 (2005) 129-131
21. Kramer H.H., Schmidt K., Leis S., Schmelz M., Sommer C., and Birklein F. Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation. Exp Neurol 195 (2005) 179-184
22. Kraenzlin M.E., Ch'ng J.L., Mulderry P.K., Ghatei M.A., and Bloom S.R. Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul Pept 10 (1985) 189-197
23. Le Greves P., Nyberg F., Terenius L., and Hokfelt T. Calcitonin gene-related peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol 115 (1985) 309-311
24. Malcangio M., and Bowery N.G. Peptide autoreceptors: does an autoreceptor for substance P exist?. Trends Pharmacol Sci 20 (1999) 405-407
25. McDowell G., Coutie W., Shaw C., Buchanan K.D., Struthers A.D., and Nicholls D.P. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 43 (1997) 329-332
26. McEwan J.R., Benjamin N., Larkin S., Fuller R.W., Dollery C.T., and MacIntyre I. Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms. Circulation 77 (1988) 1072-1080
27. Moskowitz M.A. The neurobiology of vascular head pain. Ann Neurol 16 (1984) 157-168
28. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13 (1992) 307-311
29. Olesen J., Iversen H.K., and Thomsen L.L. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4 (1993) 1027-1030
30. Paterna S., Di Pasquale P., D'Angelo A., Seidita G., Tuttolomondo A., Cardinale A., et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 43 (2000) 133-136
31. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., and Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
32. Sakai F., and Meyer J.S. Abnormal cerebrovascular reactivity in patients with migraine and cluster headache. Headache 19 (1979) 257-266
33. Sarchielli P., Alberti A., Codini M., Floridi A., and Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20 (2000) 907-918
34. Schrader H., Stovner L.J., Helde G., Sand T., and Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 322 (2001) 19-22
35. Struthers A.D., Brown M.J., Macdonald D.W., Beacham J.L., Stevenson J.C., Morris H.R., et al. Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin Sci (Lond) 70 (1986) 389-393
36. Thie A., Carvajal-Lizano M., Schlichting U., Spitzer K., and Kunze K. Multimodal tests of cerebrovascular reactivity in migraine: a transcranial Doppler study. J Neurol 239 (1992) 338-342
37. Thomas T.D., Harpold G.J., and Troost B.T. Cerebrovascular reactivity in migraineurs as measured by transcranial Doppler. Cephalalgia 10 (1990) 95-99
38. Thomsen L.L., Iversen H.K., Brinck T.A., and Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 13 (1993) 395-399
39. Tiret L., Rigat B., Visvikis S., Breda C., Corvol P., Cambien F., et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51 (1992) 197-205
40. Tronvik E., Stovner L.J., Helde G., Sand T., and Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289 (2003) 65-69
41. Tvedskov J.F., Lipka K., Ashina M., Iversen H.K., Schifter S., and Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58 (2005) 561-568
42. Uddman R., and Edvinsson L. Neuropeptides in the cerebral circulation. Cerebrovasc Brain Metab Rev 1 (1989) 230-252
43. Wiesenfeld-Hallin Z., Hokfelt T., Lundberg J.M., Forssmann W.G., Reinecke M., Tschopp F.A., et al. Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat. Neurosci Lett 52 (1984) 199-204
44. Williamson D.J., and Hargreaves R.J. Neurogenic inflammation in the context of migraine. Microsc Res Tech 53 (2001) 167-178
45. Wimalawansa S.J., and Macintyre I. Heterogeneity of plasma calcitonin gene-related peptide: partial characterisation of immunoreactive forms. Peptides 9 (1988) 407-410
46. Zaidi M., Bevis P.J., Abeyasekera G., Girgis S.I., Wimalawansa S.J., Morris H.R., et al. The origin of circulating calcitonin gene-related peptide in the rat. J Endocrinol 110 (1986) 185-190